Tech Company Financing Transactions
CytoDyn Funding Round
CytoDyn closed a $16.5 million funding round on 9/1/2026. Investors included Paulson & Co..
Transaction Overview
Company Name
Announced On
9/1/2026
Transaction Type
Venture Equity
Amount
$16,500,000
Round
Undisclosed
Investors
Proceeds Purpose
With this financing expected to fund operations into the second half of 2027, we are well positioned to focus on clinical execution and the pursuit of strategic priorities that we believe will create meaningful long-term value for our shareholders.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1111 Main Street 660
Vancouver, WA 98660
USA
Vancouver, WA 98660
USA
Phone
Website
Email Address
Overview
CytoDyn is committed to enhancing the lives of patients through target specific medicine. Our team is focused on developing leronlimab, a monoclonal antibody CCR5 receptor antagonist, as a platform drug with potential in a variety of indications in solid-tumor oncology.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jacob Lalezari
Browse more venture capital transactions:
Prev: 9/1/2026: Gridsight venture capital transaction
Next: 9/1/2026: Scopia Surgical venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. All VC database entries reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs